Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18661464 | 0.90 | KMT2A (0.43) | PDE10APPP1CAKMT2ADRD1 | |
| SCHEMBL20406574 | 0.89 | DRD1 (0.40) | PDE10ACYP17A1GPBAR1KDRTEK | |
| SCHEMBL20406667 | 0.87 | DRD1 (0.42) | PDE10APPP1CAKMT2AGPBAR1DRD1 | |
| SCHEMBL20394443 | 0.84 | DRD1 (0.39) | PDE10APPP1CAKMT2AGPBAR1KDR | |
| SCHEMBL20406580 | 0.83 | GPBAR1 (0.40) | PDE10APPP1CAKMT2AGPBAR1DRD1 | |
| SCHEMBL20394477 | 0.83 | PDE10A (0.53) | PDE10AKMT2ADRD1 | |
| SCHEMBL18661521 | 0.83 | PDE10A (0.56) | PDE10AGPBAR1KDRTEK | |
| SCHEMBL18661462 | 0.83 | GPBAR1 (0.39) | PDE10APPP1CAKMT2AGPBAR1DRD1 | |
| SCHEMBL18661506 | 0.82 | PDE10A (0.51) | PDE10ACYP17A1GPBAR1SLC22A12 | |
| SCHEMBL20406584 | 0.82 | GPBAR1 (0.41) | PDE10AGPBAR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | PDE10A 4605/4885CYP17A1 122/4885PPP1CA 3336/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | PDE10A 4605/4885CYP17A1 122/4885PPP1CA 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.